Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials

Purpose: This study aimed to compare clinically relevant outcomes following transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) using only prospective randomized clinical trials as a source of information. Mat...

Descripción completa

Detalles Bibliográficos
Autores: Casadei-Gardini, A. (Andrea)|||/items/80fdaa32-d954-44ea-a9d0-d1fc52de5982, Tamburini, E. (Emiliano)|||/items/68f0f9b3-3bab-45d0-86d8-85ecb0b8524d, Iñarrairaegui-Bastarrica, M. (Mercedes)|||/items/c0e6fd5c-24cd-4a98-8b45-f4c895e7ccd6, Frassineti, G.L. (Giovanni Luca)|||/items/48b32ddd-09cd-42ae-ab73-0472b3d76605, Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/64739
Acceso en línea:https://hdl.handle.net/10171/64739
Access Level:acceso abierto
Palabra clave:Selective internal radiation
SIRT
TARE
TACE
Outcome
Transplantation rates
Hepatología
Descripción
Sumario:Purpose: This study aimed to compare clinically relevant outcomes following transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) using only prospective randomized clinical trials as a source of information. Materials and methods: A meta-analysis was performed to compare the efficacy of TARE and TACE in treating patients with unresectable HCC. Only prospective randomized trials were included in the quantitative analysis. Overall and progression-free survival, disease control rate, and transplantation rate were the variables under analysis. Results: Overall survival at 1 year was similar between the two treatment groups (OR =1.31, 95% CI: 0.56–3.04, P=0.53). Progression-free survival at 1 year was also not statistically different between the two treatments (OR =0.23, 95% CI: 0.02–2.45, P=0.22). Although a higher proportion of patients underwent transplantation in the TARE group (30% vs 20.8%), this difference was not statistically significant (OR =0.68, 95% CI: 0.23–2.01; P=0.49). Conclusion: TARE and TACE provide similar outcomes in unresectable HCC. The role of TARE should be explored in selected patient subpopulations in future clinical trials.

Similares en LA Referencia